Bukwang Pharmaceutical Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was KRW 43,420.1 million compared to KRW 42,868.57 million a year ago. Net income was KRW 483.01 million compared to net loss of KRW 421.4 million a year ago. Basic earnings per share from continuing operations was KRW 7 compared to basic loss per share from continuing operations of KRW 6 a year ago. Diluted earnings per share from continuing operations was KRW 7 compared to diluted loss per share from continuing operations of KRW 6 a year ago. Basic earnings per share was KRW 7 compared to basic loss per share of KRW 6 a year ago.
For the six months, sales was KRW 0.00022 million compared to negative sales of KRW 0.00095 million a year ago. Net loss was KRW 4,421.77 million compared to KRW 2,541.82 million a year ago. Basic loss per share from continuing operations was KRW 65 compared to KRW 37 a year ago. Diluted loss per share from continuing operations was KRW 65 compared to KRW 37 a year ago. Basic loss per share was KRW 65 compared to KRW 37 a year ago.